ACCURAY Business Summary

Accuray Incorporated (ARAY) is a specialized radiation oncology company that designs, develops, and sells advanced medical systems for tumor treatment. The company generates revenue through two primary segments: Product, which includes the sale of its flagship CyberKnife robotic radiosurgery and Radixact/TomoTherapy helical radiation delivery platforms, and Service, which provides recurring revenue through maintenance contracts, installation, and training. As of February 2026, Accuray is executing a comprehensive organizational transformation plan to optimize its cost structure and pivot toward higher-margin service growth and commercial simplification. The company competes directly with Siemens Healthineers (Varian), Elekta AB, and Brainlab, positioning itself as a niche leader in high-precision, real-time motion-tracking radiotherapy compared to these broader-based medical technology giants. Founded in 1990 by Stanford neurosurgeon Dr. John R. Adler, Jr., the company’s early engineering was spearheaded by Peter and Russell Schonberg. The current leadership team is led by CEO Steve La Neve, a medical technology veteran with over 40 years of experience at Globus Medical and Medtronic, who was appointed in October 2025 to lead the firm's strategic turnaround. Key executives include Senior VP and CFO Ali Pervaiz, Senior VP and COO Leonel Peralta, and Senior VP and Chief Medical & Marketing Officer Seth Blacksburg, M.D. A critical figure in the current restructuring is Transformation Board Sponsor Steven F. Mayer, a former Cerberus Capital Management executive. The company maintains high institutional backing from major investors including BlackRock, Vanguard, and TCW Group, and is overseen by a board chaired by Joseph Whitters.